T

Tempus AI Inc
NASDAQ:TEM

Watchlist Manager
Tempus AI Inc
NASDAQ:TEM
Watchlist
Price: 50.49 USD -5.82%
Market Cap: $9B

ROE

-72.6%
Current
Declining
by 1 078.2%
vs 3-y average of 1 005.6%

Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.

ROE
-72.6%
=
Net Income
$-203.9m
/
Avg Total Equity
$280.8m

Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.

ROE
-72.6%
=
Net Income
$-203.9m
/
Avg Total Equity
$280.8m

Peer Comparison

Country Company Market Cap ROE
US
Tempus AI Inc
NASDAQ:TEM
8.8B USD
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.1T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
189.4B USD
Loading...
US
Danaher Corp
NYSE:DHR
149.3B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
79.3T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
34.8B CHF
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
300.3B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
34.4B USD
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
27.2B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
27.3B USD
Loading...
CN
WuXi Biologics (Cayman) Inc
HKEX:2269
167.6B HKD
Loading...

Market Distribution

Lower than 90% of companies in the United States of America
Percentile
10th
Based on 13 668 companies
10th percentile
-72.6%
Low
-155 749.7% — -2%
Typical Range
-2% — 15.9%
High
15.9% — 143 206.7%
Distribution Statistics
the United States of America
Min -155 749.7%
30th Percentile -2%
Median 8.2%
70th Percentile 15.9%
Max 143 206.7%

Tempus AI Inc
Glance View

Tempus AI Inc. stands at the forefront of the healthcare technology revolution, focusing its expertise on the convergence of artificial intelligence and big data to transform the way doctors approach precision medicine. Founded by Eric Lefkofsky in 2015, the company’s mission is to harness the power of data, equipping physicians with crucial insights that can propel patient care forward. With its sprawling genomic database, Tempus aggregates clinical and molecular information, which is then meticulously analyzed to provide actionable insights. Physicians receive comprehensive reports, offering tailored therapeutic options and clinical trial opportunities that might otherwise remain undiscovered. Monetization for Tempus hinges on its relationships with various stakeholders in the healthcare ecosystem. It primarily earns revenue through partnerships with pharmaceutical companies, where it assists in drug discovery and development by offering detailed genomic data and analytics. Moreover, Tempus collaborates with research institutes and healthcare providers who rely on its AI-driven platform to enhance clinical decision-making and improve treatment outcomes. By bridging the gap between vast datasets and intricate patient care solutions, Tempus not only facilitates better healthcare practices but also solidifies its role as a vital link in the evolving landscape of modern medicine.

TEM Intrinsic Value
42.07 USD
Overvaluation 17%
Intrinsic Value
Price
T
What is Return on Equity?
Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.
How is ROE calculated?

ROE is calculated by dividing the Net Income by the Avg Total Equity.

ROE
-72.6%
=
Net Income
$-203.9m
/
Avg Total Equity
$280.8m
What is Tempus AI Inc's current ROE?

The current ROE for Tempus AI Inc is -72.6%, which is below its 3-year median of 1 005.6%.

How has ROE changed over time?

Over the last 2 years, Tempus AI Inc’s ROE has decreased from 86.3% to -72.6%. During this period, it reached a low of -1 490.3% on Sep 30, 2024 and a high of 10 742.6% on Mar 31, 2025.

Back to Top